Abstracts tagged "systemic sclerosis and autoantibodies"

Abstract Number: 404 • 2019 ACR/ARP Annual Meeting
Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis
Julie D'Aoust¹, Valérie Leclair ², Geneviève Gyger ³, Alain Meyer ⁴, Marvin Fritzler ⁵, Océane Landon-Cardinal ⁶, Erin O'Ferrall ⁷, Jason Karamchandani ⁷, Benjamin Ellezam ⁸, Rami Massie ⁷, Minoru Satoh ⁹, Yves Troyanov ¹⁰ and Marie Hudson ¹¹, ¹McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Division of Rheumatology, Department of Medicine, Jewish General Hospital, Montreal, QC, Canada, ⁴Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Montreal Neurological Institute, Montreal, QC, Canada, ⁸Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ⁹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Myopathy is an important cause of morbidity in systemic sclerosis (SSc). Nevertheless, scleromyositis remains incompletely characterized owing at least in part to its clinical…
Abstract Number: 2594 • 2019 ACR/ARP Annual Meeting
Associations Between Antibodies to the Angiotensin II Type 1 Receptor and Endothelian-1 Type a Receptor and the Incidence of Vascular Complications in Early Diffuse Systemic Sclerosis
Kendall Downer¹, Robyn Domsic ², Carol Bentlejewski ², Adriana Zeevi ² and Lei Zhu ², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recently, the hypothesis that autoantibodies to the angiotensin II type 1 (AT1R) and endothelian-1 type A (ETAR) receptors are driving the vascular injury and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].